Virtual Biopsy Tools Democratizing Healthcare
Oncoustics creates advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. By applying AI to raw ultrasound signals, Oncoustics rapidly differentiates healthy versus diseased tissues via novel acoustic biomarkers for virtual biopsy tools, surgical guidance and drug development.
Their prospectively collected >4M+ pieces of data is the largest RF signal dataset in the world and includes clinical data on liver, prostate, kidney, breast and thyroid diseases and cancers. Initially targeting liver disease, a $65B+ global diagnostic market, Oncoustics is filing FDA submissions for the OnX liver assessment solution which has been introduced to over 70 clinics and hundreds of KOLs globally.
What We’re Looking For
Oncoustics is seeking connections with pharma companies, clinical partners, and ML/signal processing experts to advance platform capabilities, along with support in developing a regulatory and clinical strategy through introductions to cybersecurity and medical writing experts. Additionally, Oncoustics is looking to connect with billing and reimbursement experts, and gain press for their educational campaigns.
Financing
Total Raised: $11.2M. $3.2M in non-dilutive funding. $8M USD in pre-seed and seed financing rounds with top investors including Saltagen Capital, Creative Ventures and Sony Innovation Fund.
Latest News
June 18, 2024
Oncoustics Awarded INOVAIT Focus Fund to Accelerate AI-Driven Liver Diagnostics at Point of Care
Ronaldo Santiago, MD
Ophthalmologist/Ocular Oncologist w/experience in research, pharma and med device, academia and medicine.